CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2018

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

The study on the mechanism of Lentinan in improving immune function in patients with advanced NSCLC

Author: 
Xi-Xian Lou, Meng-Chu Zhu, He-Ping Lin and Chang Cai
Subject Area: 
Health Sciences
Abstract: 

Objective: To explore the possible mechanism of lentinan in improving the immune function of patients with advanced NSCLC through a variety of pathways related to lung cancer immunity, and to provide a theoretical basis for the improvement of immunity of lentinan and its anti-tumor effect. Methods: The subjects were the same as the Part Ⅰ. The fasting venous blood was taken before and after treatment. The PBMNCs were obtained after PBMNC separation, centrifugation and washing. The expression levels of PD-1 protein, PD-L1 protein, Jak2 protein, Jak3 protein, Stat3 protein, P13K protein, p-AKT protein in PBMNCs were detected by Western blot. The expression levels of PD-1 mRNA, PD-L1 mRNA, Jak2 mRNA, Jak3 mRNA, Stat3 mRNA, P13K mRNA, p-AKT mRNA in PBMNCs were detected by Real-time quantitative PCR. Results: In the PD-1/PD-L1 signaling pathway, the levels of PD-1 protein, PD-1 mRNA, PD-L1 protein and PD-L1 mRNA in PBMNC were significantly lower after treatment (P<0.05). The levels of PD-1 protein, PD-1 mRNA, PD-L1 protein and PD-L1 mRNA in the treatment group were lower than those in the control group. The difference of PD-1 protein, PD-1 mRNA, PD-L1 protein and PD-L1 mRNA before and after treatment was higher than that of the control group. (P<0.05).In JAK/STAT signaling pathway, the levels of Jak2 protein, Jak2 mRNA, Jak3 protein, Jak3 mRNA, Stat3 protein and Stat3 mRNA in PBMNC were significantly lower than those before treatment (P<0.05). Comparison between groups showed combination therapy. The levels of Jak2 protein, Jak2 mRNA, Jak3 protein, Jak3 mRNA, Stat3 protein and Stat3 mRNA in PBMNC group were lower than those in control group. The difference between Jak2 protein, Jak2 mRNA, Jak3 protein, Jak3 mRNA, Stat3 protein and Stat3 mRNA before and after treatment was higher than that of control. Group (P < 0.05).In the PI3K-AKT signaling pathway, the levels of P13K protein, P13K mRNA, p-AKT protein, p-AKT mRNA in PBMNC were significantly lower than those before treatment (P<0.05). The comparison between groups showed that the levels of P13K protein, P13K mRNA, p-AKT protein, p-AKT mRNA in PBMNC of the combined treatment group were lower than those of the control group, P13K protein, P13K mRNA, p-AKT protein, p- The difference of AKT mRNA levels before and after treatment was higher than that of the control group (P<0.05). Conclusion: Lentinan may improve the immunity of NSCLC patients through PD-1/PD-L1 signaling pathway, JAK/STAT signaling pathway and PI3K-AKT signaling pathway.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran